Novo Nordisk: Annual Report 2014 (Novo Nordisk) - Feb 7, 2015 - Anticipated expiry of active ingredient patent in US in 2021; Anticipated data protection in US until 2025; Anticipated expiry of active ingredient formulation patent in Germany in 2016; Anticipated expiry of active ingredient formulation patent in China in 2016; Anticipated expiry of active ingredient formulation patent in Japan in 2016
Anticipated patent expiry • Hemophilia
|